Added to YB: 2026-04-06
Pitch date: 2026-04-01
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
Author Info
Your fast track to micro-cap and small-cap earnings (under $2B Market Cap) insights. Get the key quarterly highlights for US and Canadian micro-cap and small-cap companies, without sifting through hundreds of press releases. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 330.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.65
P/E
12.45
EV/Sales
6.52
Sector
Pharmaceuticals
Category
growth
Cipher Pharmaceuticals Inc (TSX:CPH)
CPH.TO (earnings): FY25 rev $50.5M (+51% YoY), EPS $1.07 (+128%), adj EBITDA $28.1M (+79%) driven by transformative Natroba acquisition (July'24, $82.5M, generated $17.4M EBITDA). Repaid $35M of $40M revolver in 18mo. Launched DTC platform natroba.com (March'26) for volume growth. Pursuing M&A w/ $85M debt capacity, zero net debt, $134M tax shields. Canada approval exp. end'26. Licensing rev declined 46% on generics.
Read full article (2 min)